PD Neurotechnology is an Irish medical device company specializing in wearable monitoring systems for Parkinson's disease and other movement disorders. Founded in Dublin, the company develops FDA-cleared and CE-marked devices that provide continuous, objective measurement of motor symptoms including tremor, bradykinesia, dyskinesia, and gait disturbances. PD Neurotechnology's mission is to transform Parkinson's disease management by enabling continuous remote monitoring that was previously only possible during periodic clinic visits.
The company addresses a critical unmet need in Parkinson's disease care: the episodic nature of clinical assessment. Standard clinical rating scales like the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) capture patient status at a single point in time, missing the significant day-to-day and hour-to-hour fluctuations that characterize Parkinson's disease. PD Neurotechnology's wearable solutions provide continuous monitoring that captures these fluctuations, enabling clinicians to make more informed treatment decisions and researchers to conduct more sensitive clinical trials.
The flagship PD Monitor is a wearable device designed for continuous 24/7 monitoring of Parkinson's disease motor symptoms. The system consists of:
- Wearable Sensors: Small, lightweight accelerometers worn on the wrists and ankles that capture movement data continuously
- Mobile Application: A smartphone app that provides real-time feedback to patients and caregivers, tracks medication timing, and allows symptom logging
- Cloud Analytics Platform: A HIPAA-compliant cloud infrastructure that processes sensor data using proprietary algorithms to quantify motor symptoms
- Clinician Dashboard: A web-based portal that enables neurologists to review patient data, track disease progression, and adjust treatment plans remotely
The PD Monitor specifically quantifies:
- Tremor: Frequency (Hz), amplitude, and pattern of resting and action tremor
- Bradykinesia: Movement speed, amplitude, and rhythm abnormalities
- Dyskinesia: Involuntary movements including choreiform and dystonic movements
- Gait Parameters: Step length, cadence, stride variability, and postural sway
- Sleep Quality: Movement during sleep, REM sleep behavior disorder markers
The PMS (Parkinson's Management System) Watch is a smartwatch-based monitoring platform that provides continuous data collection in a form factor familiar to patients. While less comprehensive than the full PD Monitor system, the PMS Watch offers:
- All-day wearability with minimal patient burden
- Medication reminder alerts
- Activity tracking and exercise monitoring
- Fall detection capabilities
- Integration with electronic health records
The companion PD Tracker mobile application enables patient self-reporting that complements objective sensor data:
- Symptom diary functionality
- Medication logging with timing
- Quality of life questionnaires
- Side effect reporting
- Appointment scheduling reminders
¶ Technology and Algorithms
PD Neurotechnology's devices utilize inertial measurement units (IMUs) incorporating:
- Three-axis accelerometers: Measure linear acceleration with sensitivity to detect subtle movements
- Three-axis gyroscopes: Capture rotational movement and orientation
- Sampling rates: 100 Hz for detailed tremor frequency analysis
- Dynamic range: ±16g to capture both fine tremor and falls
The company's proprietary algorithms process raw sensor data through:
- Noise filtering: Removal of artifact from normal daily activities
- Movement detection: Identification of relevant motor events
- Feature extraction: Quantification of tremor frequency, amplitude, and pattern
- Symptom classification: ML-based classification into tremor, bradykinesia, dyskinesia
- Severity scoring: Conversion to standardized scores correlating with clinical scales
PD Neurotechnology has invested heavily in machine learning approaches:
- Supervised learning: Training on data labeled by expert neurologists using clinical rating scales
- Deep learning: Neural networks for automated feature extraction and classification
- Personalization: Individual baseline modeling to detect meaningful changes from personal norms
- Federated learning: Privacy-preserving model improvements across patient populations
PD Neurotechnology products have been validated in multiple peer-reviewed studies:
| Study |
Year |
Participants |
Findings |
| Godinho et al. |
2016 |
50 PD patients |
89% correlation with MDS-UPDRS motor scores |
| Sanchez-Ferreira et al. |
2019 |
30 PD patients |
Validated tremor quantification accuracy |
| Meijer et al. |
2019 |
100 patients |
Reliable home-based monitoring |
| Woods et al. |
2020 |
75 patients |
Digital phenotyping accuracy |
- FDA 510(k) Clearance: PD Monitor cleared for Parkinson's disease symptom monitoring
- CE Marking: Full CE marking for clinical use in European Union
- TGA Registration: Registered with Therapeutic Goods Administration in Australia
Studies demonstrate that continuous monitoring provides:
- Earlier detection: Motor fluctuations detected 3-6 months before clinical recognition
- Treatment optimization: Medication adjustments guided by objective data show 23% improvement in ON/OFF time
- Reduced hospitalizations: Remote monitoring reduces emergency visits by 31%
- Trial enrichment: Objective endpoints improve clinical trial sensitivity
In standard clinical practice, PD Neurotechnology enables:
- Remote patient monitoring: Clinicians review weekly/monthly symptom summaries without clinic visits
- Medication titration: Objective data guides levodopa dosing adjustments
- Disease progression tracking: Longitudinal data reveals subtle progression
- Caregiver support: Family members access to symptom data improves care coordination
Pharmaceutical companies utilize PD Neurotechnology for:
- Objective endpoints: Continuous measures reduce placebo response and improve signal detection
- Remote monitoring: Reduces clinic visit burden, improving patient retention
- Digital biomarker development: Standardized wearable data enables cross-trial comparisons
- At-home trials: Fully remote trial designs possible with wearable monitoring
Academic researchers employ PD Neurotechnology for:
- Natural history studies: Understanding disease progression patterns
- Biomarker validation: Correlating digital biomarkers with classical measures
- Intervention studies: Evaluating physical therapy, exercise, and device interventions
- Neurophysiology research: Investigating underlying motor control abnormalities
¶ Competitive Landscape
| Company |
Product |
Key Features |
Status |
| PD Neurotechnology |
PD Monitor |
Full-body wearable, CE/FDA cleared |
Commercial |
| Great Lakes Neurotechnologies |
Kinesia |
Wrist-worn, comprehensive |
Commercial |
| Charco Neurotech |
CUE1 |
Vibration therapy, tremor detection |
Commercial |
| Rune Labs |
StrivePD |
Apple Watch, PD management |
Commercial |
| Global Kinetics |
PKG |
Wrist-worn, medication reminder |
Commercial |
| Verily |
Study Watch |
Research-grade, multi-sensor |
Research |
PD Neurotechnology differentiates through:
- Comprehensive symptom coverage: Full spectrum from tremor to gait
- Regulatory status: Both FDA and CE clearances
- Algorithm accuracy: Published validation data
- European presence: Strong market position in EU
PD Neurotechnology maintains research partnerships with leading institutions:
- Trinity College Dublin: Algorithm development and signal processing
- University College London: Clinical validation studies
- ** King's College London**: Sleep and circadian analysis
- Medical University of Graz: Dyskinesia quantification
- AbbVie: Parkinson's disease clinical trial monitoring
- Biogen: Digital endpoint development
- Roche: Remote monitoring integration
- UCB Pharma: Patient support program integration
PD Neurotechnology is developing:
- Next-generation sensors: Smaller, longer battery life, waterproof design
- AI-powered prediction: Forecasting OFF episodes before they occur
- Multi-modal integration: Combining wearable data with smartphone cognitive tests
- Sleep monitoring: Enhanced REM sleep behavior disorder detection
- Voice analysis: Smartphone-based speech analysis for hypomimia detection
The company is expanding into:
- Essential tremor: Algorithm adaptation for tremor monitoring
- Multiple system atrophy: Differentiation from Parkinson's disease
- Progressive supranuclear palsy: Specialized monitoring algorithms
- Pediatric movement disorders: Adapted sensor sizes and algorithms